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doi:10.1016/j.jtcvs.2006.03.068bjectives: Recent studies suggest that standard uptake value on fluorodeoxyglucose
ositron emission tomography scan can predict mediastinal lymph node status in
alignant pleural mesothelioma. Because mediastinal nodal metastasis is known to be
ssociated with poor prognosis, we hypothesized that standard uptake value on fluoro-
eoxyglucose positron emission tomography might independently predict survival.
ethods: Patients with pathologically proven mesothelioma underwent fluorode-
xyglucose positron emission tomography scanning. Patients fasted and received a
inimum of 10 mCi of F18-fluorodeoxyglucose. Whole-body emission studies were
cquired, followed by whole-body transmission scans with iterative reconstruction.
n the basis of the maximal chi-square method, a standard uptake value of 10 was
hosen to classify patients as low versus high standard uptake value. Survival
robabilities for both standard uptake value groups were estimated by the Kaplan-
eier method. A Cox proportional hazards model assessed the joint influence of
tandard uptake value, histology, and stage on survival.
esults: From 1998 to 2005, 137 patients with malignant pleural mesothelioma
nderwent positron emission tomography scans. The median follow-up for all
urviving patients was 24 months. Median survivals were 9 and 21 months for the
igh and low standard uptake value groups, respectively (P  .02). In a multiva-
iable analysis, high standard uptake value tumors were associated with a 1.9 times
reater risk of death than low standard uptake value tumors (P  .01). Mixed
istology carried a 2.9 times greater risk of death than epithelioid histology (P 
01), and stages III and IV had a 1.8 times greater risk of death than stages I and II
P  .05).
onclusions: Standard uptake value greater than 10, mixed histology, and stages III
nd IV are poor risk factors in malignant pleural mesothelioma. These findings
uggest that fluorodeoxyglucose positron emission tomography can be used to
tratify patients for treatment and clinical trials.
alignant pleural mesothelioma (MPM) is a rare disease for which there is
no universally accepted therapy. Treatment varies from observation alone
to complex multimodality therapy consisting of surgery, radiation, and
hemotherapy. To direct treatment and to stratify patients for clinical trials, predic-
ors of survival are needed. Currently, histology and tumor stage are the best
redictors of survival. Computed tomography (CT) and magnetic resonance imag-
ng, the most widely used methods of clinical staging, frequently fail to stage disease
ccurately at the time of diagnosis.1 Approximately 25% of patients who under
urgical exploration for resection are found to have unresectable tumors because of
ocally advanced (T4) disease undetected by imaging studies.2
We previously investigated positron emission tomography (PET) as a preoper-
tive staging tool and found that it identified occult distant metastasis in 10% of
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TSatients, but that it did not predict T4 disease identified at
urgery.3 However, a high PET standard uptake va
SUV) did correlate with the presence of N2 disease at the
ime of resection in MPM. Because SUV seems to reflect
he tumor biology of MPM, we hypothesized that maximum
ET SUV independently predicts survival in MPM.
The objectives of this study were to determine whether
ET SUV predicted survival and to identify an SUV cutoff
alue that stratifies patients into high- and low-risk groups.
ethods
atients
rom April 1998 to January 2005, all patients with MPM who
nderwent fluorodeoxyglucose (FDG)-PET scanning were identi-
ed from an institutional database. Clinical data were also obtained
rom a prospective institutional database. Data acquisition and
nalysis were approved by our institutional review board. The
athologic diagnosis of mesothelioma was confirmed by histologic
eview, relevant immunohistochemical analysis, and electron mi-
roscopy when necessary. All patients were considered for surgery
f they had potentially resectable lesions identified by CT scan of
he chest and upper abdomen and adequate cardiopulmonary
unction.
ET Evaluation
ET scans were acquired on dedicated BGO-based systems, in-
luding the GE Advance (Munich, Germany, Siemens HR, and
iemens Biograph scanners (Erlangen, Germany). All patients
ere instructed to fast for 6 hours before the administration of
DG. After a minimum of 45 minutes post-injection of at least 10
Ci of FDG, whole-body emission scans were performed, with
od source-based transmission scans to allow for iterative recon-
truction with segmented attenuation correction.
Patients were clinically staged by PET with the American Joint
ommission on Cancer and the Union Internationale Contre le
ancer staging system.4,5 The SUV was calculated according 
tandard methods based on the uptake of FDG in grams per
illiliter corrected for the injected dose of FDG adjusted for the
atient’s weight. To calculate the maximal SUV in the tumor, we
lectronically threshholded the images so that only the hottest
oxel of tumor was seen. A region of interest was drawn around
he hottest voxel on the transaxial slice of the iteratively recon-
tructed images, and the SUV maximal value, corrected for body
eight, was recorded.
tatistical Methods
Wilcoxon test was used to compare the median SUV of the
Abbreviations and Acronyms
CT  computed tomography
FDG  fluorodeoxyglucose
MPMmalignant pleural mesothelioma
PET  positron emission tomography
SUV  standard uptake valuepithelioid and non-epithelioid tumor types. A hazard function c
64 The Journal of Thoracic and Cardiovascular Surgery ● Octolotting SUV versus predicted median survival time was con-
tructed to visualize the functional relationship between SUV as a
ontinuous variable and survival. The maximal chi-square method
as used to identify an optimal SUV cutoff that separated patients
nto high- and low-risk groups.6 Kaplan-Meier analysis was fir
erformed on patients grouped by the accepted predictors of sur-
ival (stage and histologic subtype) and then performed on patients
rouped by low and high SUV. Finally, Kaplan-Meier survival
robabilities were assessed on patients with epithelioid tumor
istology for all the 4 possible categories by using SUV as a
ichotomous variable (high and low), as well as stages I and II and
tages III and IV.
A Cox proportional hazard analysis was used to identify pre-
ictors of survival. The initial model was performed including all
nown predictors of survival. Insignificant variables were then
ropped using a stepwise procedure, thus yielding the final model.
esults
emographic Information
total of 137 consecutive patients with biopsy-proven,
reviously untreated MPM underwent FDG-PET scanning
s part of their initial staging evaluation. These patients
ncluded 96 men and 31 women with a median age of 67
ears (range 35-85 years). Some 106 patients (76%) had
umors of epithelioid histology, 27 of mixed subtype and 4
f sarcomatoid subtype. Three patients had stage I disease,
1 patients had stage II disease, 47 patients had stage III
isease, and 56 patients had stage IV disease. Seventy
atients underwent extrapleural pneumonectomy, 17 pa-
ients underwent pleurectomy/decortication, 31 patients un-
erwent exploratory thoracotomy without resection, and 19
atients did not undergo any surgical procedures. The me-
ian follow-up of surviving patients was 24 months.
tandard Uptake Value in Relation to Tumor
istology
he median SUV of the epithelioid tumors was 6.2, which
as not significantly different from tumors of mixed histol-
gy for which the median SUV was 7.8 (P  .9). Four
arcomatoid tumors had a median SUV of 3.8 (Table 
tandard Uptake Value in Relation to Survival
he estimated median survival for each value of SUV is
hown in Figure 1.7 The function demonstrates a near line
ABLE 1. Positron emission tomography standard uptake
alue in relation to tumor histology
Histology n Median SUV
Epithelioid 106 6.2
Mixed 27 7.8
Sarcomatoid 4 3.8
UV, Standard uptake value.orrelation of increasing SUV with poor survival. The max-
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G
TSmal chi-square method selected an SUV of 10 as the best
hreshold to dichotomize patients into good or poor prog-
osis groups.
urvival Analysis
nown prognostic factors were assessed by the Kaplan-
eier survival method. Patients with epithelioid tumors had
significantly better overall survival than those with other
umor histology (median survival of 24 months vs 9 months,
  .01) (Figure 2). The survival of patients with sta
igure 1. Hazard function plotting predicted median survival by
UV. SUV, Standard uptake value.(Figure 2. Overall survival by histology.
The Journal of ThoracicI
nd II tumors was compared with that of patients with stage
II and IV tumors. The median survival was 41 months for
atients with stage I and II tumors and 17 months for stage
II and IV tumors (P  .02) (Figure 3).
The influence of high and low SUV on survival was
ssessed (Figure 4). The median survival of patients wi
UV of less than 10 was 21 months compared with a
edian survival of 9.7 months in the group with an SUV of
0 or more. This difference was statistically significant by
og rank test (P  .02).
An analysis was performed grouping patients with epi-
helioid and non-epithelioid tumor histology by high and
ow SUV (Figure 5). Overall survival was assessed ac
ll 4 categories, and a statistically significant difference was
bserved (P  .01). Of note, 20% of the patients who had
oth a low SUV and epithelioid tumor histology are alive
eyond 5 years. In contrast, none of the patients who had
oth a high SUV and non-epithelioid tumor histology were
live at 2 years.
A multivariable analysis was performed using the Cox
roportional hazards method. The most commonly used
redictors were included in this model along with SUV.
owever, type of operation, patient age and sex, and tumor
aterality were not statistically significant predictors of sur-
ival. Our final model shows that patients whose tumors had
n SUV of greater than 10 had a hazard ratio for death of 1.9
hen compared with patients with an SUV of less than 10
igure 3. Overall survival by stage. TNM, Tumor node metastasis.P .01). Patients with non-epithelioid tumor histology had
and Cardiovascular Surgery ● Volume 132, Number 4 765
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G
TShazard ratio for death of 2.9 when compared with patients
ith epithelioid tumor histology (P  .01). Patients with
tage III and IV tumors had a hazard ratio of 1.8 when
ompared with patients with stage I and II tumors (P  .05)
igure 4. Overall survival by PET SUV. SUV, Standard uptake
alue.
igure 5. Overall survival by SUV and histology. SUV, Standard
optake value.
66 The Journal of Thoracic and Cardiovascular Surgery ● OctoTable 2). When SUV is used as a continuous variable 
ox model, the hazard ratio is 1.05 (95% confidence inter-
al 1.02-1.08, P  .01). Each unit increase in SUV in-
reases the risk of death by 5%.
iscussion
urrent imaging modalities lack the ability to depict the ex-
ent of disease accurately in MPM. Previous studies have
hown that CT and magnetic resonance imaging provide
natomic information that is imprecise in the preoperative
taging of MPM.1 Approximately 25% of patients underg-
ng attempt at surgical resection are found to be unresect-
ble at the time of thoracotomy.2 Several prior small studie
discussed next) investigated the utility of FDG PET scan in
esothelioma.
The first study included 22 patients with pathologi-
ally proven MPM.8 The goal of this study was to eval
hether PET could help distinguish between benign and
alignant pleural disease. PET demonstrated a sensitivity
f 92% (22/24) and a specificity of 75% (3/4). SUV data
ere available in only 18 patients. A survival analysis was
ot performed. The main point was that differentiating
enign from malignant pleural disease still required patho-
ogic confirmation; however, PET did seem to be useful in
uiding surgical biopsy.
In 1999 the same group evaluated the prognostic value of
DG PET in 17 patients who had both SUV data and a
iagnosis of mesothelioma.9 A high SUV seemed to cor-
ate with short survival in 6 deceased patients. However,
urviving patients and a patient who died postoperatively
ere excluded from the analysis. Kaplan-Meier analysis
sing an arbitrary division at an SUV of 4 demonstrated a
odest difference in survival; however, interpretation of
hese results is difficult because more than half (n  9) of
he patients in this series had non-epithelioid histology,
hich does not reflect the predominance of epithelioid
istology among patients with mesothelioma. In addition,
he majority of patients with a high SUV also had higher
tage tumors and unfavorable histology (mixed or sarcoma-
oid). A multivariate analysis to control for the influence of
reatment (surgical or medical), stage, and histology was not
erformed. Therefore, meaningful conclusions are difficult
o draw from this study.
In 2000, Schneider and colleagues10 evaluated the utility
ABLE 2. Multivariable analysis of prognostic variables
Hazard ratio Confidence interval P value
UV  10 1.9 1.2-2.9 0.01
on-epithelioid 2.9 1.8-4.5 0.01
tage III-IV 1.8 1.0-3.1 0.05
UV, Standard uptake value.f PET scan in 18 patients evaluated preoperatively. SUV
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G
TSata were available in only 9 patients. Two patients were
xcluded from surgery on the basis of extrathoracic disease.
lthough PET correctly identified 2 positive lymph nodes
hat were missed by CT scan, it falsely identified 2 nodes as
eing positive. This study did not evaluate the role of SUV
n predicting survival, and the small number of patients
imits the validity of the analyses.
In a previous article we reported scans between 1998 and
002, 60 preoperatively and 3 to assess disease recurrence
fter surgery.3 Increased FDG uptake was seen in all b
umor, which was very early stage disease (IA). PET find-
ngs yielded sensitivities of only 19% and 11% for tumor
tage and nodal status, respectively. However, a high SUV
n the primary tumor correlated with the presence of N2
isease. PET correctly identified supraclavicular N3 or M1
isease in 6 patients. Although PET did not reliably identify
he local extent of tumor or mediastinal nodal metastases,
xtrathoracic metastases were identified in 10%, thereby
bviating inappropriate thoracotomy.
Several other small studies exist that investigated the use
f PET scanning in mesothelioma but focused primarily on
taging rather than survival.11-13 Accurate patient selection
or treatment has become increasingly important because of
he development of improved chemotherapy regimens (eg,
emetrexed and cisplatin) and the need to decide which
atients might benefit from induction therapy before resec-
ion. Our previous analysis in 63 patients showed a survival
enefit for those with tumors with an SUV of less than 4.
owever, there were only 13 patients in this category.14 Our
urrent study is more than double the size of the prior study,
nd a similar analysis suggests that an SUV of 10 is a more
obust value to dichotomize patients into high and low
roups. As greater numbers of patients are studied in the
uture it is possible that 3 values may be found to separate
atients with mesothelioma by prognosis: an SUV less than
and greater than 4, and an SUV less than 10 and greater
han 10.
The demographic data in this study are consistent with
hose usually observed in MPM: The majority of patients
ere male, and most tumors were of epithelioid histology.
he differences in survival between epithelioid and non-
pithelioid subtypes and among tumor stages are consistent
ith previously published data.15,16
We found no significant difference in the median SUV
etween epithelioid and non-epithelioid tumors. Although
he median SUV of pure sarcomatoid lesions seems lower,
here were only 4 such patients in this series (all in advanced
tage). Indeed, a previous study of 17 patients with MPM
eported 1 sarcomatoid tumor with an SUV of 8.25.8 Al-
hough there are too few patients with sarcomatoid MPM in
his study to draw definitive conclusions regarding SUV
evels in relationship to this histology, it seems that the SUV
ay reflect tumor biology independent of tumor histology.
The Journal of ThoracicPET SUV was not used to direct treatment; therefore, a
election bias based on SUV results should not exist. It
eems that increasing SUV is a predictor of poor prognosis.
his finding is not unexpected given the fact that SUV is a
eflection of metabolic rate and nodal involvement, which
sually correlates with more biologically aggressive tumors
nd poor survival. To date, histology and TNM stage have
een the best predictors of survival. The final Cox model
lso revealed that patients with an SUV greater than 10 had
1.9 times greater risk of death than those with an SUV less
han 10, that non-epithelioid histology had a 2.8 times
reater risk of death than epithelioid histology, and that
tage III and IV tumors had a 1.8 times greater risk of death
han stage I and II tumors. On the basis of these findings, it
eems useful to stratify future clinical trials by SUV, his-
ology, and stage.
onclusions
ET seems to be a useful tool for staging and predicting the
rognosis of MPM. Previous studies have shown the utility
f PET in identifying occult metastatic disease,3 and this
tudy demonstrates the ability to stratify patients for sur-
ival when a maximal SUV of 10 is chosen to separate
atients into good and poor prognosis groups. When SUV,
istology, and stage are taken together, further separation of
ubgroups may be observed that reflect significant differ-
nces in survival, low SUV, epithelioid histology, and low
tage predicting the best survival. Although validation of
hese results in larger studies is needed, it now seems that
he combination of SUV, histology, and stage provide a
onvenient and clinical method of identifying good and
oor prognosis patient groups in MPM.
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